GastroPlus User Group

A free online community of GastroPlus users –
share best practices and exchange new ideas


 

This Month In GastroPlus™ Modeling

GastroPlus™ 9.5 – Now Available

View Release Notes

 


 

Watch Webinar Replay


Stay up-to-date with conferences, scientific talks, webinars, workshops, and more.

Daejeon, South Korea
July 10-12, 2017

Cambridge, Massachusetts
September 11-13, 2017

Tokyo, Japan
October 16-20, 2017

View our calendar

With over 850 members and growing…interact with your peers around the globe!*

Regulatory implications of software version

What are your favorite GastroPlus modelling tips from the scientific literature?

Predicted plasma concentration vs time profile is not matching the observed profile in the terminal phase.

I have a NCE that is showing moderate to high clearance in rodents. The data from hepatocytes and ABT in vivo suggests that metabolism is not CYP mediated. How should we use GP to predict human PK?

*note: must sign into LinkedIn and be a member of the GastroPlus User Group to review and contribute


New peer-reviewed journal publications citing various applications of GastroPlus software.

A strategy for early risk predictions of clinical drug-drug interactions involving the GastroPlusTM DDI module for time-dependent CYP inhibitors.

Lipophilic salts of poorly soluble compounds to enable high-dose lipidic SEDDS formulations in drug discovery.

Studies on Core-Shell Nanocapsules of Felodipine: In Vitro-In Vivo Evaluations.

In vitro and in vivo evaluation of gastro-retentive carvedilol loaded chitosan beads using GastroPlus™.

Prediction of Losartan Active Carboxylic Acid Metabolite Exposure Following Losartan Administration Using Static and Physiologically-Based Pharmacokinetic Models.

Development and qualification of physiologically based pharmacokinetic models for drugs with atypical distribution behavior: A desipramine case study.

Food Effect on Oral Bioavailability: Old and New Questions

Identification and characterisation of a salt form of Danirixin with reduced pharmacokinetic variability in patient populations.

Integrating in vitro, modeling, and in vivo approaches to investigate warfarin bioequivalence.

Comparison of oral absorption properties among different bisphosphonates by using a newly developed physiologically based pharmacokinetic model.